Abbott Laboratories (ABT)

81.94
2.40 2.90
NYSE : Health Technology
Prev Close 84.37
Open 83.84
Day Low/High 81.37 / 84.25
52 Wk Low/High 65.22 / 88.76
Volume 6.21M
Avg Volume 4.95M
Exchange NYSE
Shares Outstanding 1.77B
Market Cap 150.05B
EPS 1.30
P/E Ratio 52.41
Div & Yield 1.28 (1.47%)

Latest News

Abbott Laboratories Achieves #56 Analyst Rank, Surpassing TJX Companies

Abbott Laboratories Achieves #56 Analyst Rank, Surpassing TJX Companies

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #56 spot from TJX Companies , according to ETF Channel. Below is a chart of Abbott Laboratories versus TJX Companies plotting their respective rank within the S&P 500 over time (ABT plotted in blue; TJX plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Abbott And Intoximeters Partner To Keep Roads Safer By Bringing Together Industry-leading Technology For Drug And Alcohol Testing

Abbott And Intoximeters Partner To Keep Roads Safer By Bringing Together Industry-leading Technology For Drug And Alcohol Testing

- Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers

Weekly Roundup

We are staying the course, using bouts of panic to buy up the stocks of high-quality companies on discounts.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

Another Check on Every Portfolio Name: Where Would We Buy?

We are taking a moment to provide price levels for nearly every position in the portfolio.

Last Week's Portfolio Changes

We initiated two new positions and exited another during a busy week of earnings.

Weekly Roundup

While the trade war is clearly intensifying, we are viewing the market through a buyers' lens, waiting for pullbacks that improve our basis.

Chipotle, Boot Barn, Nutanix: 'Mad Money' Lightning Round

Chipotle, Boot Barn, Nutanix: 'Mad Money' Lightning Round

Jim Cramer takes a look at Chipotle, Boot Barn, Nutanix, HEXO, Anaplan, Sonic Automotive, VMware, Lithia Motors and more.

Trade Noose Tightens: Cramer's 'Mad Money' Recap (Thursday 8/1/19)

Trade Noose Tightens: Cramer's 'Mad Money' Recap (Thursday 8/1/19)

Jim Cramer puts the new tariffs in context and tells investors how to survive the trade war: Stand by some techs, and companies without China exposure.

Trimming Abbott Before the Closing Bell

We still love the long-term story here.

Last Week's Portfolio Changes

We exited one position and made a bevy of ratings changes last week.

Weekly Roundup

Markets see solid performance during busy earnings season week.

Addressing Another Batch of Common Member Questions

Today's a good time to answer some more member questions!

Go-Go Growth: Cramer's 'Mad Money' Recap (Tuesday 7/23/19)

Go-Go Growth: Cramer's 'Mad Money' Recap (Tuesday 7/23/19)

Jim Cramer says higher sales, higher prices, and demand from emerging markets seem to be fueling a return to the days of great senior growth stocks.

Pfizer, eBay, Cloudera: 'Mad Money' Lightning Round

Pfizer, eBay, Cloudera: 'Mad Money' Lightning Round

Jim Cramer weighs in on Pfizer, eBay, Cloudera, Cadence Systems, CRISPR Therapeutics, Moderna, Tandem Diabetes Care, and more.

Checking in on Every Portfolio Name: Where Would We Buy?

We are providing buy price levels for nearly every position in the AAP portfolio.

Last Week's Portfolio Changes

We updated price targets on three portfolio holdings last week.

Weekly Roundup

Markets pull back as earnings season gets underway.

A Tale of Two Economies: Cramer's 'Mad Money' Recap (Wednesday 7/17/19)

A Tale of Two Economies: Cramer's 'Mad Money' Recap (Wednesday 7/17/19)

Jim Cramer says the consumer economy is in great shape, but the business economy is a different story. He wants the Fed to pay attention.

Video: Jim's Daily Rundown for Wednesday

Jim shares his thoughts on Abbott Laboratories' earnings, the headwinds facing big tech, and much more!

Abbott Labs Reports Earnings

Overall this was a very strong quarter that once again demonstrated Abbott's ability to cut through the cyclical headwinds plaguing many companies.

Abbott Laboratories Hits Record High As FreeStyle Libre Sales Drive Q2 Earnings

Abbott Laboratories Hits Record High As FreeStyle Libre Sales Drive Q2 Earnings

Abbott Laboratories posted stronger-than-expected second quarter earnings Wednesday, and boosted its full-year profit guidance, as sales of its FreeStyle Libre glucose monitoring system surged following FDA approval in 2017.

U.S. Monetary Policy, Trading Lockheed, Netflix and United Rentals: Market Recon

U.S. Monetary Policy, Trading Lockheed, Netflix and United Rentals: Market Recon

Preventing the U.S. dollar from appreciating too aggressively while repairing credit conditions are 'job freaking one'.

Dow Futures Edge Higher As Markets Look to FAANG Earnings to Extend Record Rally

Dow Futures Edge Higher As Markets Look to FAANG Earnings to Extend Record Rally

U.S. equity futures edged higher, potentially lifting Wall Street to fresh record peaks again Wednesday, as investors await the first of six major tech sector earnings reports later today that could make-or-break the recent stock market rally.

Abbott Reports Second-Quarter 2019 Results

Abbott Reports Second-Quarter 2019 Results

- Accelerated and sustainable growth driven by strong performance across portfolio

Abbott Receives U.S. Approval Of Next-Generation MitraClip®, Bringing New Enhancements To Abbott's Leading MitraClip Platform

Abbott Receives U.S. Approval Of Next-Generation MitraClip®, Bringing New Enhancements To Abbott's Leading MitraClip Platform

- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair

Weekly Roundup

Markets surge to new records as Fed Chairman Jerome Powell signals rate cuts are likely.

Next Week's Earnings Previews

Here are 6 companies we'll be following.

TheStreet Quant Rating: A (Buy)